Arthur Kaser is the Professor of Gastroenterology and a Wellcome Trust Senior Investigator at the University of Cambridge. He qualified in medicine from Leopold Franzens University Innsbruck where he also completed a thesis on Type I interferons. He then undertook postdoctoral training in Innsbruck and at Harvard Medical School’s Brigham and Women’s Hospital, as a Max Kade and Schroedinger Fellow. Arthur returned to Innsbruck where he started his independent laboratory and then moved to Cambridge in 2011. Arthur’s research in mucosal immunology has been recognised by many awards including being elected a Fellow of the Academy of Medical Sciences in 2017 and a ERC Consolidator Award. He serves as Course Co-Director of the Cambridge-MedImmune PhD Programme and is Consultant Gastroenterologist at Addenbrookes Hospital with a specialist interest in Inflammatory Bowel Disease. He also serves as Visiting Professor with the Norwegian Primary Sclerosing Cholangitis Research Centre at the University of Oslo and is a member of the Scientific Committee of the European Crohn’s and Colitis Organisation.
Professor Kaser’s lab is internationally recognised for defining mechanisms causing inflammatory bowel disease (IBD), and has made major contributions into general understanding of genetically-affected pathways at the host-environment interface. His lab uses a variety of techniques including complex genetic murine models to uncover the biological pathways regulated by risk genes of IBD. His lab have discovered how impaired autophagy and mediators of the unfolded protein response pathway lead to IBD. His lab also discovered a novel immunometabolic mechanism that determines risk for Crohn’s disease, leprosy and systemic juvenile arthritis. He also serves as a clinical investigator and is involved in the design and delivery of early and late phase clinical trials exploring new mechanisms of action in inflammatory bowel disease. He leads the new Gastrointestinal Disease theme of the Cambridge NIHR Biomedical Research Centre.